Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGEM Cullinan Therapeutics

Trading 12-22 10:47:19 EST

10.22

+0.54

+5.58%

High10.30	Low9.65	Vol370.76K
Open9.88	D1 Closing9.68	Amplitude6.66%
Mkt Cap603.76M	Tradable Cap368.48M	Total Shares59.08M
T/O3.71M	T/O Rate1.03%	Tradable Shares36.06M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGEM","market":"US","secType":"STK","nameCN":"Cullinan Therapeutics","latestPrice":10.22,"timestamp":1766418434836,"preClose":9.68,"halted":0,"volume":370758,"delay":0,"floatShares":36055085,"shares":59076259,"eps":-3.680879,"marketStatus":"Trading","change":0.54,"latestTime":"12-22 10:47:19 EST","open":9.88,"high":10.295,"low":9.65,"amount":3705362.1256440002,"amplitude":0.066632,"askPrice":10.25,"askSize":1,"bidPrice":10.18,"bidSize":141,"shortable":3,"etf":0,"ttmEps":-3.680879,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"listingDate":1610082000000,"exchange":"NASDAQ","adjPreClose":9.68,"preHourTrading":{"tag":"盘前","latestPrice":10,"preClose":9.68,"latestTime":"09:29 EST","volume":1896,"amount":18617.63928,"timestamp":1766413799999},"postHourTrading":{"tag":"盘后","latestPrice":10.04,"preClose":9.68,"latestTime":"19:51 EST","volume":141643,"amount":1371163.3997,"timestamp":1766191903074},"volumeRatio":1.283639,"impliedVol":0.6433,"impliedVolPercentile":0.288},"requestUrl":"/m/hq/s/CGEM","defaultTab":"news","newsList":[{"id":"2590934905","title":"Cullinan Therapeutics Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2590934905","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590934905?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:27","pubTimestamp":1765286820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 08:27 ET (13:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"gpt_icon":0},{"id":"2590346432","title":"Wedbush Raises Price Target on Cullinan Therapeutics to $34 From $25, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590346432","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590346432?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:52","pubTimestamp":1765284761,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics (CGEM) has an average rating of buy and mean price target of $27.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGEM"],"gpt_icon":0},{"id":"2590345821","title":"Cullinan Therapeutics Inc : Wedbush Raises Target Price to $34 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2590345821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590345821?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:13","pubTimestamp":1765282395,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nFWN3XF0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"2590882318","title":"U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico","url":"https://stock-news.laohu8.com/highlight/detail?id=2590882318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590882318?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:07","pubTimestamp":1765264045,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico Dec 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AstraZeneca,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3XF0GQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DH","BWA","DE","IE00B775SV38.USD","KR","COLL","IE00BK4W5M84.HKD","DLTR","GKOS","MACW.SI","ALEX","CIEN","03165","DAN","GM","ALGN","CFLT","ANIP","APD","AVGO","ELAN","CIM","DOCS","CL","GLXY","AAPL","AR","DYN","IE00BZ9MQY76.HKD","AMPH","AAL","AMRX","ADBE","BTSG","LU0154236417.USD","CAH","CCRN","FMC","LU0997586432.USD","CRC","ARWR","AZN.UK","DAL","COR","CGEM","AZN","NVST","XRAY","LU2552382058.USD","LU0964806797.USD"],"gpt_icon":0},{"id":"2590357546","title":"Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses","url":"https://stock-news.laohu8.com/highlight/detail?id=2590357546","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590357546?lang=en_us&edition=fundamental","pubTime":"2025-12-09 00:59","pubTimestamp":1765213191,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics  said Monday that data from its early-stage trial evaluating the CLN-049 monotherapy candidate in acute myeloid leukemia and myelodysplastic syndrome showed \"promising\" efficacy, including multiple complete responses.For acute myeloid leukemia, the company said the complete response to complete remission with partial hematologic recovery rate was 31%, at the highest target dose tested to date.Efficacy endpoints of the study include complete response rate and composite complete response rate, the company said.Initial dose escalation results in 45 patients demonstrated a favorable safety profile across all doses assessed, the company said.Development of CLN-049 will proceed under the US Food and Drug Administration's Fast Track designation, the company said.Dose escalation is continuing in this ongoing phase 1 study, with expansion groups planned in early 2026, it added.Shares of the company were up 12% in recent Monday trading.Price: 11.66, Change: +1.07, Percent C","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CGEM","SSI"],"gpt_icon":0},{"id":"2590352635","title":"BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590352635","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590352635?lang=en_us&edition=fundamental","pubTime":"2025-12-09 00:17","pubTimestamp":1765210640,"startTime":"0","endTime":"0","summary":"BRIEF-Cullinan Therapeutics Says Phase 1 CLN-049 Monotherapy Demonstrates Promising EfficacyDec 8 (Reuters) - Cullinan Therapeutics Inc CGEM.O:CULLINAN THERAPEUTICS INC - PHASE 1 CLN-049 MONOTHERAPY D","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"2589354952","title":"Cullinan Therapeutics Inc - Phase 1 Cln-049 Monotherapy Demonstrates Promising Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354952?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:34","pubTimestamp":1765208050,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"2589354640","title":"Cullinan Therapeutics Reports Promising Phase 1 Results for CLN-049 in Relapsed/Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2589354640","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589354640?lang=en_us&edition=fundamental","pubTime":"2025-12-08 23:31","pubTimestamp":1765207869,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics Inc. has announced updated clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 bispecific T cell engager, in patients with relapsed or refractory acute myeloid leukemia  and myelodysplastic syndrome . The results, which include a 31% CR/CRh rate at the highest target dose tested and a favorable safety profile across all doses, were presented as an oral presentation at the 67th American Society of Hematology  Annual Meeting and Exposition on December 8, 2025. CLN-049 has recently been granted Fast Track designation by the U.S. FDA, and dose escalation in the ongoing Phase 1 study continues, with expansion cohorts planned for early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL6dhyR4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","CGEM","LU0314104364.USD","NDAQ","BK4588","BK4139","BK4112","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","LU2095319765.USD"],"gpt_icon":0},{"id":"2588732724","title":"Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049 in Relapsed/Refractory AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2588732724","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588732724?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590420,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL5X3X7F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","BK4139","LU2210149790.SGD","CGEM","BK4585","IE00BGHQF748.EUR","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2588672478","title":"Cullinan Therapeutics Receives FDA Fast Track Designation for Cln-049, a Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2588672478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588672478?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2LB436:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"2586778261","title":"Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2586778261","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586778261?lang=en_us&edition=fundamental","pubTime":"2025-11-27 00:20","pubTimestamp":1764174015,"startTime":"0","endTime":"0","summary":"Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics recently announced the initiation of a rolling New Drug Application submission to the U.S. FDA for accelerated approval of zipalertinib, targeting EGFR exon 20 insertion-mutated non-small cell lung cancer after chemotherapy.\nThis milestone builds on zipalertinib’s Breakthrough Therapy Designation and leverages data from the REZILIENT1 Phase 1/2 trial involving previously treated patients.\nWe'll explore how progress toward FDA...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/why-cullinan-therapeutics-cgem-is-up-381-after-fda-filing-fo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/why-cullinan-therapeutics-cgem-is-up-381-after-fda-filing-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"2586263055","title":"Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2586263055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586263055?lang=en_us&edition=fundamental","pubTime":"2025-11-26 22:55","pubTimestamp":1764168919,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has reiterated their bullish stance on CGEM stock, giving a Buy rating on November 24. Soumit Roy has given his Buy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-cullinan-therapeutics-driven-by-promising-aml-treatment-developments-and-strong-market-potential-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-cullinan-therapeutics-driven-by-promising-aml-treatment-developments-and-strong-market-potential-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"gpt_icon":0},{"id":"2586040104","title":"Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586040104","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586040104?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:00","pubTimestamp":1764108045,"startTime":"0","endTime":"0","summary":"Jennifer Michaelson, Chief Scientific Officer, reported a disposal of common shares of Cullinan Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL8qKbGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"2586491526","title":"Cullinan Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491526","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491526?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:37","pubTimestamp":1764005820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 12:37 ET (17:37 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"gpt_icon":0},{"id":"2586499521","title":"Cullinan Therapeutics Up Over 23%, on Pace for Largest Percent Increase Since April 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586499521?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:53","pubTimestamp":1764003180,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics, Inc.  is currently at $11.65, up $2.18 or 23.02%. --Would be highest close since Jan. 6, 2025, when it closed at $11.78. --On pace for largest percent increase since April 26, 2024, when it rose 31.43%. --Currently up three consecutive days; up 37.87% over this period. --Down 4.35% year-to-date; on pace for worst year since 2022, when it fell 31.63%. --Down 78.19% from its all-time closing high of $53.42 on March 10, 2021. --Down 7.10% from 52 weeks ago , when it closed at $12.54. --Down 13.38% from its 52-week closing high of $13.45 on Nov. 29, 2024. --Traded as high as $11.87; highest intraday level since Jan. 30, 2025, when it hit $11.92. --Up 25.34% at today's intraday high; largest intraday percent increase since April 26, 2024, when it rose as much as 33.58%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"2585812920","title":"Cullinan Management Ends Development of CLN-617","url":"https://stock-news.laohu8.com/highlight/detail?id=2585812920","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585812920?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:03","pubTimestamp":1763762604,"startTime":"0","endTime":"0","summary":"Cullinan Management ( ($CGEM) ) has provided an announcement. On November 18, 2025, Cullinan Amber Corp., a subsidiary of Cullinan Therapeutics, In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cullinan-management-ends-development-of-cln-617?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cullinan-management-ends-development-of-cln-617?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"2585269491","title":"Cullinan Therapeutics- Cullinan Amber Notified Mit Decision to Terminate Exclusive Patent License Agreement for Cln-617","url":"https://stock-news.laohu8.com/highlight/detail?id=2585269491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585269491?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:35","pubTimestamp":1763760934,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0QW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"2585512664","title":"Cullinan Amber Ends CLN-617 License Agreement with MIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2585512664","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585512664?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:31","pubTimestamp":1763760664,"startTime":"0","endTime":"0","summary":"Cullinan Amber Corp. to Terminate MIT License Agreement and Return CLN-617 Patent Rights. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL3j64NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"gpt_icon":0},{"id":"2585155031","title":"Taiho, Cullinan Therapeutics initiate rolling submission of NDA for zipalertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2585155031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585155031?lang=en_us&edition=fundamental","pubTime":"2025-11-21 00:10","pubTimestamp":1763655027,"startTime":"0","endTime":"0","summary":"Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a New Drug ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taiho-cullinan-therapeutics-initiate-rolling-submission-of-nda-for-zipalertinib-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taiho-cullinan-therapeutics-initiate-rolling-submission-of-nda-for-zipalertinib-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CGEM"],"gpt_icon":0},{"id":"2585156818","title":"Optimistic Buy Rating for Cullinan Management Driven by Promising Drug Pipeline and Upcoming Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2585156818","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585156818?lang=en_us&edition=fundamental","pubTime":"2025-11-21 00:05","pubTimestamp":1763654733,"startTime":"0","endTime":"0","summary":"Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Cullinan Management, boosting the price target to $26.00. Robert Burns has given...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-cullinan-management-driven-by-promising-drug-pipeline-and-upcoming-catalysts-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-cullinan-management-driven-by-promising-drug-pipeline-and-upcoming-catalysts-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cullinantherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1879},{"period":"1month","weight":0.1456},{"period":"3month","weight":0.5613},{"period":"6month","weight":0.2621},{"period":"1year","weight":-0.116},{"period":"ytd","weight":-0.2053}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.082426},{"month":2,"riseRate":0.6,"avgChangeRate":0.024211},{"month":3,"riseRate":0.2,"avgChangeRate":-0.103725},{"month":4,"riseRate":0.4,"avgChangeRate":0.06919},{"month":5,"riseRate":0.6,"avgChangeRate":-0.004749},{"month":6,"riseRate":0.4,"avgChangeRate":-0.054955},{"month":7,"riseRate":0.6,"avgChangeRate":0.01398},{"month":8,"riseRate":0.4,"avgChangeRate":0.037827},{"month":9,"riseRate":0,"avgChangeRate":-0.146845},{"month":10,"riseRate":0.6,"avgChangeRate":0.085935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.037651},{"month":12,"riseRate":0.2,"avgChangeRate":-0.058577}],"exchange":"NASDAQ","name":"Cullinan Therapeutics","nameEN":"Cullinan Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cullinan Therapeutics,CGEM,Cullinan Therapeutics股票,Cullinan Therapeutics股票老虎,Cullinan Therapeutics股票老虎国际,Cullinan Therapeutics行情,Cullinan Therapeutics股票行情,Cullinan Therapeutics股价,Cullinan Therapeutics股市,Cullinan Therapeutics股票价格,Cullinan Therapeutics股票交易,Cullinan Therapeutics股票购买,Cullinan Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}